These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24040868)

  • 1. Confronting the residual cardiovascular risk beyond statins: the role of fibrates, omega-3 fatty acids, or niacin, in diabetic patients.
    Christou GA; Rizos EC; Mpechlioulis A; Penzo C; Pacchioni A; Nikas DN
    Curr Pharm Des; 2014; 20(22):3675-88. PubMed ID: 24040868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrates and niacin: is there a place for them in clinical practice?
    Wierzbicki AS; Viljoen A
    Expert Opin Pharmacother; 2014 Dec; 15(18):2673-80. PubMed ID: 25318657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triglycerides and endothelial function: molecular biology to clinical perspective.
    Kajikawa M; Higashi Y
    Curr Opin Lipidol; 2019 Oct; 30(5):364-369. PubMed ID: 31348023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative cardiometabolic effects of fibrates and omega-3 fatty acids.
    Han SH; Oh PC; Lim S; Eckel RH; Koh KK
    Int J Cardiol; 2013 Sep; 167(6):2404-11. PubMed ID: 23452884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering medications for children and adolescents.
    Miller ML; Wright CC; Browne B
    J Clin Lipidol; 2015; 9(5 Suppl):S67-76. PubMed ID: 26343214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?
    Drexel H
    Fundam Clin Pharmacol; 2009 Dec; 23(6):687-92. PubMed ID: 19682084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonstatin therapies for management of dyslipidemia: a review.
    Sando KR; Knight M
    Clin Ther; 2015 Oct; 37(10):2153-79. PubMed ID: 26412799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal pharmacotherapy to combat the atherogenic lipid triad.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Curr Opin Cardiol; 2011 Sep; 26(5):403-11. PubMed ID: 21730827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
    Chapman MJ; Redfern JS; McGovern ME; Giral P
    Pharmacol Ther; 2010 Jun; 126(3):314-45. PubMed ID: 20153365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic impact of non-statin lipid lowering therapies.
    Goyal P; Igel LI; LaScalea K; Borden WB
    Curr Atheroscler Rep; 2014 Feb; 16(2):390. PubMed ID: 24395391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic Effects of Non-statin Lipid-Lowering Therapies.
    Collins PD; Sattar N
    Curr Cardiol Rep; 2016 Dec; 18(12):133. PubMed ID: 27864787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Combination Cholesterol-Lowering Therapy and Triglyceride-Lowering Therapy on Medical Costs in Patients With Type 2 Diabetes Mellitus.
    Nichols GA; Reynolds K; Olufade T; Kimes TM; O'Keeffe-Rosetti M; Sapp DS; Anzalone D; Fortmann SP
    Am J Cardiol; 2017 Feb; 119(3):410-415. PubMed ID: 27890243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Fibrates Monotherapy in People with Diabetes and High Cardiovascular Risk in Primary Care: A French Nationwide Cohort Study Based on National Administrative Databases.
    Roussel R; Chaignot C; Weill A; Travert F; Hansel B; Marre M; Ricordeau P; Alla F; Allemand H
    PLoS One; 2015; 10(9):e0137733. PubMed ID: 26398765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.